Psoriasis is an autoimmune disease in which your skin grows too quickly, about 10 times faster than normal. The skin piles up excessively which results in thickened plaques that is characterized as psoriasis. Psoriasis clinical trials aim to reduce the effects of and eventually eradicate psoriasis.
So, what makes the skin grow so fast? An inaccurate response from the immune system. The immune system acts to prevent and fight against infections, but with autoimmune diseases, it is overly active and functions irregularly. An overactive immune system, in the case of psoriasis, leads to inflammation of the skin causing the skin to grow faster than it should producing redness, scaling, and itching. Researchers discovered three key components in the immune system that triggers psoriasis:
A protein molecule called tumor necrosis factor (TNF) is overproduced. TNF helps fight off infections and tumors, but when there is excessive TNF produced, it causes inflammation i the skin.
Activated white blood cells, called T cells, can also produce an inflammatory reaction in the skin.
Another protein like TNF, called interleukin-23 (IL-23) is found to be produced abundantly in psoriasis, causing skin lesions.
Despite the discovery that these molecules and cells of the immune system are overactive and causing inflammation that leads to psoriasis, it is still unclear what causes these parts of the immune system to become overactive.
Treatments being used in our psoriasis clinical trials aim to block the interactions between the cells and molecules in the immune system blocking the inflammatory pathways. Learn more here about our ongoing psoriasis clinical trials or give us a call at 508-755-0201.